Jim Simons Olema Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 29,400 shares of OLMA stock, worth $185,808. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,400

Previous 53,200 44.74%

Holding current value

$185,808

Previous $575,000 38.96%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$10.41 - $16.46 $247,758 - $391,748	-23,800 Reduced 44.74%	29,400 $351,000
Q2 2024 Aug 09, 2024	BUY	$8.73 - $13.99 $464,436 - $744,268	53,200 New	53,200 $575,000
Q4 2023 Feb 13, 2024	SELL	$10.53 - $17.14 $1.44 Million - $2.35 Million	-136,889 Reduced 44.09%	173,611 $2.44 Million
Q3 2023 Nov 14, 2023	BUY	$8.19 - $12.98 $144,144 - $228,448	17,600 Added 6.01%	310,500 $3.84 Million
Q2 2023 Aug 11, 2023	BUY	$3.22 - $9.65 $114,954 - $344,505	35,700 Added 13.88%	292,900 $2.65 Million
Q1 2023 May 12, 2023	SELL	$2.55 - $4.97 $22,950 - $44,730	-9,000 Reduced 3.38%	257,200 $892,000
Q4 2022 Feb 13, 2023	SELL	$2.27 - $3.76 $259,461 - $429,768	-114,300 Reduced 30.04%	266,200 $652,000
Q3 2022 Nov 14, 2022	BUY	$2.72 - $5.88 $256,675 - $554,872	94,366 Added 32.98%	380,500 $1.05 Million
Q2 2022 Aug 12, 2022	BUY	$2.04 - $4.61 $79,156 - $178,877	38,802 Added 15.69%	286,134 $1.17 Million
Q1 2022 May 13, 2022	BUY	$3.89 - $9.43 $962,121 - $2.33 Million	247,332 New	247,332 $1.05 Million
Q4 2021 Feb 11, 2022	SELL	$8.75 - $30.71 $856,625 - $3.01 Million	-97,900 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$22.96 - $30.13 $2.25 Million - $2.95 Million	97,900 New	97,900 $2.7 Million

Others Institutions Holding OLMA

# of Institutions

136

Shares Held

58.7M

Call Options Held

141K

Put Options Held

23.1K

View Full List

About Olema Pharmaceuticals, Inc.

Ticker OLMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,419,600
Market Cap $255M
Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...

More about OLMA

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account